Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Luminarie
Deal Size : Undisclosed
Deal Type : Licensing Agreement
TaiGen Out-Licensed Taigexyn® to Luminarie Canada for Canada, Australia and New Zealand
Details : Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs.
Brand Name : Taigexyn
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 30, 2020
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Luminarie
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
